As the Senate Committee on Health, Education, Labor and Pensions holds a hearing on how competition can lower prescription drug prices, No Patient Left Behind’s executive director, Priscilla VanderVeer, shared the following statement.
No Patient Left Behind Welcomes Priscilla VanderVeer as
Executive Director. VanderVeer brings decades of experience advancing patient-centered policy at the intersection of innovation, access, and affordability.
Plans have increased patients’ prescription drug out-of-pocket costs by 36%, on average, since 2021
Outdated Cost-Effectiveness Analysis (CEA) Methodology Abroad Can Delay Access to Life-Saving Medicines for Patients in the U.S. and Globally and Disincentivize Future Innovation
86 percent of respondents shared concerns that state-run Prescription Drug Affordability Boards (PDABs) will limit treatment options; 51 percent said medicines prescribed by their doctor were denied by their insurer
“If a doctor prescribes a treatment and the insurer authorizes it, the copay should be affordable.”